InvestorsHub Logo
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

Re: Moanrch post# 29361

Thursday, 04/25/2013 7:58:34 AM

Thursday, April 25, 2013 7:58:34 AM

Post# of 80490
Don't forget ASCO abstract for '113...


8) Abstract #8031
First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.
D. R. Camidge, MD, PhD
Poster Board: #20

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.